A drug maker has said it will supply bulk manufacturing of the drug gavis-con to pharmaceutical bottles makers.
Key points:Pharmaceutical manufacturers would be able to make bulk orders for gavis capsules and tablets, but not pills or capsulesGavis-Con is used to treat chronic pain and to treat a range of other conditionsA group of pharmacies is working with manufacturers to develop a supply chain that would allow bulk orders to be made for the drugThe announcement by Gavis-Co will give pharmaceutical manufacturers greater control over the supply of their drugs.
The company said the move will allow them to better ensure their products are of a high quality.
It said it would start by providing bulk order fulfilment services for bulk orders of gavins.
“Pharmaceutically, the bulk order is just a delivery channel.
It’s not something that can be automated.
It requires the assistance of pharmacists to ensure that the order is delivered on time and at the correct value,” said Philip Rucker, head of research and development at GavisCon.”
Gavis capsules are typically delivered by courier.
The bulk order could be delivered by truck, via the rail network, or other transportation methods.”
The bulk order provider will be able, by the way, to take full advantage of their existing supply chain to deliver the bulk orders in bulk.
“Pharmacy chain, not pharmacy, should make decisions about bulk order supplyGavisCon is currently available only through a small number of pharmacies.
The group will begin to allow other pharmacies to make a bulk order.”
There will be an opportunity for pharmacists, and ultimately other suppliers, to offer bulk order delivery to the pharmacies,” Mr Rucker said.”
They’ll be able make a call on whether or not they’re going to fulfil the bulk ordered orders, and then they’ll be in a position to make the decision on whether they’re interested in the bulk or not.
“If they’re not interested in that, they can simply go ahead and fulfil the order.”
A new supply chain would allow pharmacists more control over bulk ordersA group called Pharmaceutical Innovation Australia has worked with pharmaceutical companies to develop the bulk supply chain.
“Our goal is to build a new supply chains model that provides pharmacists with greater control of the bulk purchase of their medications, and provides pharmacist with better understanding of what the patient needs, what the drug is, and what they are purchasing in the pharmaceutical supply chain,” said Dr Michelle Young, an expert in pharmaceutical supply chains.
“We are looking at how we can provide greater information and transparency to pharmacists in order to ensure they can make better decisions about what they purchase.”
Pharmacists would be allowed to make one order for every 30 gavis capsules.
Pharmacist-run pharmacies would have greater responsibility for bulk order fulfillmentPharmacies could also be responsible for bulk ordering, with the group responsible for ensuring the proper quantity and quality of the product being sold.
“It would allow pharmacist-led pharmacists greater control and flexibility when making bulk order deliveries to pharmacies,” Ms Young said.
Mr Rucker and Mr Young said a large portion of bulk orders are shipped to retailers for sale, which means there would be a greater need for a new system to ensure pharmacist control over their supply chain and the supply chain management of their drug.
“You have a large volume of orders that are going to retail stores and you want to be sure you’re getting the right amount of drugs, but you don’t want to have a system that is essentially a warehouse where you’re not even sure what your pharmacy is getting,” Dr Young said.
“Pharma companies have struggled to provide quality for the bulk purchases of gavi capsules and pills because of the need to keep the pills safe, because of concerns about their toxicity and because there are few alternative options.
Pharma giants such as Pfizer and Johnson & Johnson have struggled with supply chain quality, leading to an increase in overdoses.
The Gavis capsules, which are made from a combination of human and animal cells, were the first pill to be approved for use in humans by the US Food and Drug Administration.
The drug has been available since the late 1980s and is now approved by the FDA for use by adults aged 18 to 65.
Topics:health,drugs-and-substance-abuse,pharmacology,health-policy,pharma-in-pharma,phoenix-0812Contact Kate O’KeefeMore stories from Arizona